AMLX vs BIIB

For growth investors, Biogen Inc.

(BIIB) is the stronger pick with 1. 4% revenue growth year-over-year, versus -100. 0% for Amylyx Pharmaceuticals, Inc. (AMLX). Biogen Inc. (BIIB) offers the better valuation at 22. 6x trailing P/E (13. 7x forward), making it the more compelling value choice. Analysts rate Amylyx Pharmaceuticals, Inc. (AMLX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Amylyx Pharmaceuticals, Inc.

(AMLX) delivered a total return of -23. 0%, compared to -49. 6% for Biogen Inc. (BIIB). Over 10 years, the gap is even starker: AMLX returned -17. 4% versus BIIB's -18. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Biogen Inc.

(BIIB) is the lower-risk stock at 0. 39β versus Amylyx Pharmaceuticals, Inc. 's 1. 47β — meaning AMLX is approximately 280% more volatile than BIIB relative to the S&P 500. On balance sheet safety, Amylyx Pharmaceuticals, Inc. (AMLX) carries a lower debt/equity ratio of 2% versus 38% for Biogen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Biogen Inc.

(BIIB) is pulling ahead at 1. 4% versus -100. 0% for Amylyx Pharmaceuticals, Inc. (AMLX). On earnings-per-share growth, the picture is similar: Amylyx Pharmaceuticals, Inc. grew EPS 65. 5% year-over-year, compared to -21. 1% for Biogen Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Biogen Inc.

(BIIB) is the more profitable company, earning 13. 2% net margin versus 0. 0% for Amylyx Pharmaceuticals, Inc. — meaning it keeps 13. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BIIB leads at 19. 1% versus 0. 0% for AMLX. At the gross margin level — before operating expenses — BIIB leads at 70. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AMLX: 76.

1% to $24. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Biogen Inc.

(BIIB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 39)). Both have compounded well over 10 years (BIIB: -18. 2%, AMLX: -17. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.